TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03352674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Ezelin
Description: Insulin Glargine (Ezelin) once daily at individually adjusted dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine Pen Injector [Lantus]
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Study: NCT02892630

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT03402295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib, cyclophosphamide, thalidomide, dexamethasone
Description: Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib, cyclophosphamide, thalidomide, dexamethasone
Description: Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
Study: NCT00115076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
Study: NCT02904772

Intervention type: DRUG
Group type: OTHER
Intervention: alipogene tiparvovec
Description: A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.

Intervention type: DRUG
Group type: OTHER
Intervention: alipogene tiparvovec
Description: A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: IV bolus methylprednisolone 1mg/kg half hour prior to administration

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: IV bolus methylprednisolone 1mg/kg half hour prior to administration

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporins
Description: Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
Study: NCT02487914

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)
Description: drug delivery through interferential current.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 10% was sprayed at the identified region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interferential current
Study: NCT01615367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, Exercise, and Wellness (NEW) psychotherapy
Description: NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typically consists of at least one FDA-approved mood stabilizer
Description: Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
Study: NCT01416519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) facial mask
Description: After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted deep inspiration technique
Description: After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
Study: NCT02597764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Urotherapy
Study: NCT02623725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine (5-dose formulation)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo, NaCl 0.9%
Description: 0.5 mL, Subcutaneous
Study: NCT01864707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + acupuncture
Description: Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care+mbsr
Description: Patients of this group receive mindfulness based stress reduction in addition to usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Patients in this group will follow the same treatment for fatigue they received at study entry
Study: NCT02509429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm
Description: The insuline used is usual patient insuline. There is no specific insulin for this protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm
Description: The insuline used is usual patient insuline. There is no specific insulin for this protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend
Description: The insuline used is usual patient insuline. There is no specific insulin for this protocol
Study: NCT03347682

Intervention type: OTHER
Intervention: Satisfaction with Prosthesis -SATPRO
Description: questionnaire 1

Intervention type: OTHER
Intervention: Nottingham Health Profile-NHP
Description: questionnaire 2

Intervention type: OTHER
Intervention: Prosthesis donning and doffing questionnaire
Description: questionnaire 3
Study: NCT00676702

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus
Description: A high-fat liquid meal of 500 ml of Ensure Plus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase in combination with Ensure Plus
Description: 3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
Study: NCT02509429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend
Description: The insuline used is usual patient insuline. There is no specific insulin for this protocol
Study: NCT00941915

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT Prostate
Description: Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
Study: NCT01776034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE Group Lifestyle counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Lifestyle Counseling
Study: NCT01721226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Arm (computer-based CARE+ Corrections tool)
Description: Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Educational video on opiate overdose prevention
Description: Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
Study: NCT03058926

Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.

Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.

Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
Study: NCT01424501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine GSK 692342
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine GSK 692342
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine GSK 692342
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 2 doses
Study: NCT03530267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept + mLV5FU2
Description: Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX7
Description: Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
Study: NCT01978041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared with non fluoridated water
Description: Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared with fluoridated water
Description: Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non fluoridated water
Description: Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoridated water
Description: Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared to provide a fluoride dose of 60 ug F/kg
Description: Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared to provide a fluoride dose of 120 ug F/kg
Description: Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
Study: NCT02202343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: school based health and nutrition education
Study: NCT00724984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I.
Study: NCT01212393

Intervention type: BEHAVIORAL
Intervention: reminders
Description: In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
Study: NCT01361100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncoral® test
Description: The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
Study: NCT00660179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan (ACT-064992)
Description: Tablet, 3 mg dosage, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan (ACT-064992)
Description: Tablet, 10 mg dosage, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo, once daily
Study: NCT03432169

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga (stretching plus mindfulness)
Description: Stretching plus mindfulness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching alone
Study: NCT01736670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol spray
Study: NCT00852787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin immune fab
Description: Intravenously one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin immune fab
Description: Intravenously one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin immune fab
Description: Intravenously one time
Study: NCT04951869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protescal gel
Description: Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
Study: NCT00852787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously one time
Study: NCT02032498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
Study: NCT02289807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
Study: NCT00636285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSYX-A110
Description: BSYX-A110, Dosed intravenously, 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSYX-A110
Description: BSYX-A110, Dosed intravenously, 10 mg/kg
Study: NCT00853151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: 14 mg subcutaneous injection 1 time a week for 5 weeks
Study: NCT04595825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101)
Description: Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
Study: NCT00853151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: 14 mg subcutaneous injection 1 time a week for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: 14 mg subcutaneous injection 1 time a week for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT223
Description: subcutaneous injection once a day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT223
Description: subcutaneous injection once a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LY2428757
Description: subcutaneous injection 1 time a week for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for TT223
Description: subcutaneous injection once a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TT223
Description: subcutaneous injection once a day for 4 weeks
Study: NCT00291018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement
Description: Total Disc Replacement using ProDisc-C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: Anterior Cervical Discectomy and Fusion
Study: NCT01800630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine HCl Oral Formulation
Study: NCT01504412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: Oral tablets administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: Oral tablets administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: Oral tablets administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsules
Description: Pregabalin oral capsules 150 mg administered twice a day
Study: NCT03045718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy
Description: The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Horticultural Therapy
Description: The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
Study: NCT00511134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
Study: NCT00850954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information on secondhand smoke and supporting smoker in quitting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive smoking cessation materials based on TTM